166 related articles for article (PubMed ID: 19020542)
41. Autophagy induction by Bcr-Abl-expressing cells facilitates their recovery from a targeted or nontargeted treatment.
Crowley LC; Elzinga BM; O'Sullivan GC; McKenna SL
Am J Hematol; 2011 Jan; 86(1):38-47. PubMed ID: 21132731
[TBL] [Abstract][Full Text] [Related]
42. Fas-mediated modulation of Bcr/Abl in chronic myelogenous leukemia results in differential effects on apoptosis.
Selleri C; Maciejewski JP; Pane F; Luciano L; Raiola AM; Mostarda I; Salvatore F; Rotoli B
Blood; 1998 Aug; 92(3):981-9. PubMed ID: 9680367
[TBL] [Abstract][Full Text] [Related]
43. 5-Fluorouracil-resistant CD34+ cell population from peripheral blood of CML patients contains BCR-ABL-negative progenitor cells.
Jazwiec B; Mahon FX; Pigneux A; Pigeonnier V; Reiffers J
Exp Hematol; 1995 Dec; 23(14):1509-14. PubMed ID: 8542939
[TBL] [Abstract][Full Text] [Related]
44. ATR-Chk1 axis protects BCR/ABL leukemia cells from the lethal effect of DNA double-strand breaks.
Nieborowska-Skorska M; Stoklosa T; Datta M; Czechowska A; Rink L; Slupianek A; Koptyra M; Seferynska I; Krszyna K; Blasiak J; Skorski T
Cell Cycle; 2006 May; 5(9):994-1000. PubMed ID: 16687921
[TBL] [Abstract][Full Text] [Related]
45. Tyrphostin AG957, a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity restores beta1 integrin-mediated adhesion and inhibitory signaling in chronic myelogenous leukemia hematopoietic progenitors.
Bhatia R; Munthe HA; Verfaillie CM
Leukemia; 1998 Nov; 12(11):1708-17. PubMed ID: 9823945
[TBL] [Abstract][Full Text] [Related]
46. Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function.
Xiao M; Ai H; Li T; Rajoria P; Shahu P; Li X
Biochem Biophys Res Commun; 2016 Apr; 472(4):610-6. PubMed ID: 26966074
[TBL] [Abstract][Full Text] [Related]
47. Inhibition of BCR-ABL expression with antisense oligodeoxynucleotides restores beta1 integrin-mediated adhesion and proliferation inhibition in chronic myelogenous leukemia hematopoietic progenitors.
Bhatia R; Verfaillie CM
Blood; 1998 May; 91(9):3414-22. PubMed ID: 9558400
[TBL] [Abstract][Full Text] [Related]
48. E1A overcomes the apoptosis block in BCR-ABL+ leukemia cells and renders cells susceptible to induction of apoptosis by chemotherapeutic agents.
Stiewe T; Parssanedjad K; Esche H; Opalka B; Pützer BM
Cancer Res; 2000 Jul; 60(14):3957-64. PubMed ID: 10919674
[TBL] [Abstract][Full Text] [Related]
49. Genomic instability in myeloid malignancies: increased reactive oxygen species (ROS), DNA double strand breaks (DSBs) and error-prone repair.
Sallmyr A; Fan J; Rassool FV
Cancer Lett; 2008 Oct; 270(1):1-9. PubMed ID: 18467025
[TBL] [Abstract][Full Text] [Related]
50. Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells: AS-ODN as effective purging agents.
Wu AG; Joshi SS; Chan WC; Iversen PL; Jackson JD; Kessinger A; Pirruccello SJ; Sanger WG; Sharp JG; Verbik DJ
Leuk Lymphoma; 1995 Dec; 20(1-2):67-76. PubMed ID: 8750625
[TBL] [Abstract][Full Text] [Related]
51. The sensitivity of chronic myeloid leukemia CD34 cells to Bcr-Abl tyrosine kinase inhibitors is modulated by ceramide levels.
Wang J; Hu J; Jin Z; Wan H
Leuk Res; 2016 Aug; 47():32-40. PubMed ID: 27244255
[TBL] [Abstract][Full Text] [Related]
52. [Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia].
Zhu XZ; Yu YZ; Fang YM; Liang Y; Lü QH; Xu RZ
Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(27):1903-6. PubMed ID: 16255985
[TBL] [Abstract][Full Text] [Related]
53. Fluorescence in situ hybridization: a highly efficient technique of molecular diagnosis and predication for disease course in patients with myeloid leukemias.
Amare PS; Baisane C; Saikia T; Nair R; Gawade H; Advani S
Cancer Genet Cytogenet; 2001 Dec; 131(2):125-34. PubMed ID: 11750052
[TBL] [Abstract][Full Text] [Related]
54. BCR/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations.
Stoklosa T; Poplawski T; Koptyra M; Nieborowska-Skorska M; Basak G; Slupianek A; Rayevskaya M; Seferynska I; Herrera L; Blasiak J; Skorski T
Cancer Res; 2008 Apr; 68(8):2576-80. PubMed ID: 18413724
[TBL] [Abstract][Full Text] [Related]
55. Impact of BCR/ABL gene expression on the proliferative rate of different subpopulations of haematopoietic cells in chronic myeloid leukaemia.
Primo D; Flores J; Quijano S; Sanchez ML; Sarasquete ME; del Pino-Montes J; Gaarder PI; Gonzalez M; Orfao A
Br J Haematol; 2006 Oct; 135(1):43-51. PubMed ID: 16939497
[TBL] [Abstract][Full Text] [Related]
56. IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation.
Massimino M; Consoli ML; Mesuraca M; Stagno F; Tirrò E; Stella S; Pennisi MS; Romano C; Buffa P; Bond HM; Morrone G; Sciacca L; Di Raimondo F; Manzella L; Vigneri P
Carcinogenesis; 2014 May; 35(5):1132-43. PubMed ID: 24445143
[TBL] [Abstract][Full Text] [Related]
57. Gene therapy for chronic myelogenous leukemia (CML): a retroviral vector that renders hematopoietic progenitors methotrexate-resistant and CML progenitors functionally normal and nontumorigenic in vivo.
Zhao RC; McIvor RS; Griffin JD; Verfaillie CM
Blood; 1997 Dec; 90(12):4687-98. PubMed ID: 9389683
[TBL] [Abstract][Full Text] [Related]
58. Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair.
Majsterek I; Sliwinski T; Poplawski T; Pytel D; Kowalski M; Slupianek A; Skorski T; Blasiak J
Mutat Res; 2006 Jan; 603(1):74-82. PubMed ID: 16388976
[TBL] [Abstract][Full Text] [Related]
59. Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis.
Koschmieder S; Göttgens B; Zhang P; Iwasaki-Arai J; Akashi K; Kutok JL; Dayaram T; Geary K; Green AR; Tenen DG; Huettner CS
Blood; 2005 Jan; 105(1):324-34. PubMed ID: 15331442
[TBL] [Abstract][Full Text] [Related]
60. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.
Chu S; Holtz M; Gupta M; Bhatia R
Blood; 2004 Apr; 103(8):3167-74. PubMed ID: 15070699
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
